Minimed Group (STU:B8S) Research & Development: €182 Mil (TTM As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:B8S Minimed Group Inc STU:B8S
20 GF Score
Price €16.60
! 3 Warning Signs
View Full Analysis

What is Minimed Group Research & Development?

Minimed Group STU:B8S 20 Research & Development is €182 Mil as of Apr. 2026. GuruFocus rates STU:B8S with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Minimed Group's Research & Development for the three months ended in Apr. 2026 was €85 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Apr. 2026 was €182 Mil.

Minimed Group  (STU:B8S) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Minimed Group Research & Development Related Terms

Minimed Group Research & Development Historical Data

* Premium members only.

The historical data trend for Minimed Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group Research & Development Chart

Minimed Group Annual Data
Trend Apr23 Apr24 Apr25 Apr26
Research & Development
391.25 407.28 388.04 383.04

Minimed Group Quarterly Data
Apr24 Jan25 Apr25 Oct25 Jan26 Apr26
Research & Development Get a 7-Day Free Trial 108.19 95.23 0.00 97.01 84.65
STU:B8S
20GF Score
Minimed Group Inc STU:B8S
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minimed Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €182 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €182 Mil mean?
Minimed Group (STU:B8S) has a Research & Development of €182 Mil as of Apr. 2026. Research and development expense is the total cost for research and development activities. View historical data on Minimed Group and its competitors.
Is Minimed Group's Research & Development too high?
Minimed Group's current Research & Development is €182 Mil. Overall, Minimed Group has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's Research & Development compare to MMSI and NVST?
Minimed Group's Research & Development of €182 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Minimed Group and its competitors. Minimed Group's current Research & Development is €182 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (STU:B8S) has a current Research & Development of €182 Mil. The current Research & Development is €182 Mil. Minimed Group's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Minimed Group (STU:B8S), the current Research & Development is €182 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges MMED:USA
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
20GF Score

Get the complete analysis for STU:B8S

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.60
Price